Physician profile
Norman Roth
NPI 1568828259
$4,424.42
in general payments reported to CMS, 2019-2025
26 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $285 · 2021: $528 · 2022: $771 · 2023: $936 · 2024: $931 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $790.77 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $544.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $509.51 | 2019-2022 | |
| Pfizer INC. | $452.61 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.81 | 2020-2024 | Wainua |
| Novartis Pharmaceuticals Corporation | $230.85 | 2021-2025 | |
| Cvrx, INC. | $216.26 | 2023 | Barostim Neo System |
| Amgen INC. | $209.03 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $197.30 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $145.83 | 2020-2023 | |
| Esperion Therapeutics, INC. | $142.04 | 2023-2025 | Nexletol |
| Scpharmaceuticals INC. | $130.41 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $77.53 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.83 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $68.37 | 2019-2025 | Amvuttra, Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $62.35 | 2019-2023 | Evkeeza |
| Genzyme Corporation | $52.73 | 2023 | |
| Abbott Laboratories | $51.15 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $51.06 | 2024 | Arcalyst |
| Heartflow, INC. | $46.59 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $37.37 | 2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $25.38 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.12 | 2019 | |
| Itamar Medical INC | $17.82 | 2021 | |
| Terumo Medical Corporation | $14.53 | 2025 | Tr Band, Glidesheath Slender |
| Medtronic, INC. | $13.52 | 2024 | Symplicity G3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.